FemTech

As the FemTech industry experiences significant growth in addressing the needs of women’s health, innovations are rapidly emerging to tackle the gender health gap through advanced technologies and interdisciplinary approaches.

This women-centric focus highlights previously unmet needs and supports the drive for tailored healthcare solutions. However, addressing specific conditions such as menstrual health, reproductive technology, and female oncology presents its challenges, making it imperative to develop culturally sensitive, reliable methods for diverse subpopulations of women, ensuring accessibility and efficacy of emerging technologies.

HGF’s accomplished FemTech team are experts in patent drafting, prosecution, appeals, FTO and infringement opinions, and litigation for large corporate firms, SMEs, universities, and overseas associates. Often working with experts in developmental biology, microbiome technologies, and big data technology companies, our attorneys, with backgrounds in Life Sciences, Chemistry, Electronics, Engineering, and Trade Marks, blend specialist knowledge with critical insights into rapidly evolving FemTech solutions.

We are dedicated to empowering women through innovation, ensuring that intellectual property protection generates new revenue streams, creating substantial business value, and attracting investors.

Latest updates

HGF

Patent restoration

Inadvertent or accidental loss of patent rights can be distressing for patent holders and indeed for IP practitioners. The most common reason for restoration is when a patent has lapsed …

Read article

SPCs for Combination Products – Will CJEU need to look again?

Key takeaways National courts have diverged on the interpretation of the EU Court of Justice’s latest decisions on SPCs for combination products – in particular on whether data in the …

Read article
HGF logo

PRESS RELEASE - HGF strengthens Life Sciences practice with appointment of Dr Russell Thom

HGF has strengthened its European Life Sciences practice with the appointment of Dr Russell Thom, who joins the firm as a Partner 1st August 2026. Russell brings more than 25 …

Read article
Event - 16th September 2026

Basel seminar - New developments in SPCs

VENUE – Der Teufelhof Basel, The Archaeological Cellar Join us on Wednesday 16th September 5:30 – 8:00 pm (CEST) for our seminar on the latest developments in Supplementary Protection Certificates …

Event details

Playing Loose – CJEU asked to decide on combination SPCs

In a new referral (C-262/26), the EU’s Court of Justice has been asked to decide whether a medicine which receives a marketing authorisation (MA) as a monotherapy, but labelled with …

Read article
HGF logo

HGF Ranked Highly in UK WIPR Trade Mark Rankings

We are happy to announce that the WIPR rankings are now live and HGF has been highly ranked.  HGF has been recognised as:  Highly Recommended in Non-Contentious  The results detail …

Read article
AI software

New 'Technical Character' Guidance Formalised by UKIPO Practice Note

The UK Intellectual Property Office (UKIPO) has now released formal guidance for examining UK patent applications directed to software and AI inventions. The practice note comes almost six months since …

Read article

Excipient or active ingredient? Look to the marketing authorisation…

In his recently issued (non-binding) Opinion in the Halozyme referral to the Court of Justice of the EU (C-456/24), the Advocate General has delivered a decisive “no” to the question …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our femtech specialists.